Boston Scientific Co. (NYSE:BSX) EVP Sells $671,228.34 in Stock

Boston Scientific Co. (NYSE:BSX) EVP John Bradley Sorenson sold 6,389 shares of the company’s stock in a transaction on Wednesday, February 12th. The stock was sold at an average price of $105.06, for a total value of $671,228.34. Following the transaction, the executive vice president now owns 24,293 shares of the company’s stock, valued at approximately $2,552,222.58. The trade was a 20.82 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

John Bradley Sorenson also recently made the following trade(s):

• On Friday, February 7th, John Bradley Sorenson sold 6,528 shares of Boston Scientific stock. The stock was sold at an average price of $104.97, for a total value of $685,244.16.
• On Thursday, January 2nd, John Bradley Sorenson sold 4,119 shares of Boston Scientific stock. The stock was sold at an average price of $90.02, for a total value of $370,792.38.

Boston Scientific Stock Performance

Shares of NYSE BSX opened at $106.20 on Friday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.02 and a current ratio of 1.48. The firm has a market cap of $156.51 billion, a price-to-earnings ratio of 84.96, a P/E/G ratio of 2.79 and a beta of 0.80. The business’s 50-day simple moving average is $96.44 and its 200-day simple moving average is $88.19. Boston Scientific Co. has a 52 week low of $65.33 and a 52 week high of $107.17.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 18.11% and a net margin of 11.07%. As a group, equities research analysts expect that Boston Scientific Co. will post 2.83 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Royal Bank of Canada boosted their price target on Boston Scientific from $105.00 to $116.00 and gave the stock an “outperform” rating in a research report on Thursday, February 6th. TD Cowen boosted their price target on Boston Scientific from $100.00 to $110.00 and gave the stock a “buy” rating in a research report on Thursday, December 12th. Bank of America boosted their price target on Boston Scientific from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Tuesday, October 22nd. Mizuho boosted their price target on Boston Scientific from $100.00 to $110.00 and gave the stock an “outperform” rating in a research report on Thursday, October 24th. Finally, Wells Fargo & Company upped their price objective on Boston Scientific from $100.00 to $118.00 and gave the company an “overweight” rating in a report on Thursday, February 6th. One research analyst has rated the stock with a hold rating, twenty-two have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $107.39.

Institutional Trading of Boston Scientific

Several hedge funds have recently added to or reduced their stakes in the business. Gallagher Fiduciary Advisors LLC boosted its stake in Boston Scientific by 13.0% during the 4th quarter. Gallagher Fiduciary Advisors LLC now owns 6,985 shares of the medical equipment provider’s stock valued at $624,000 after purchasing an additional 802 shares during the period. Wahed Invest LLC boosted its stake in Boston Scientific by 6.3% during the 4th quarter. Wahed Invest LLC now owns 37,921 shares of the medical equipment provider’s stock valued at $3,387,000 after purchasing an additional 2,242 shares during the period. Itau Unibanco Holding S.A. bought a new stake in Boston Scientific during the 4th quarter valued at approximately $43,000. Keel Point LLC boosted its stake in Boston Scientific by 12.0% during the 4th quarter. Keel Point LLC now owns 4,276 shares of the medical equipment provider’s stock valued at $382,000 after purchasing an additional 457 shares during the period. Finally, Caisse DE Depot ET Placement DU Quebec increased its stake in shares of Boston Scientific by 7.4% in the 4th quarter. Caisse DE Depot ET Placement DU Quebec now owns 1,832,594 shares of the medical equipment provider’s stock valued at $163,687,000 after buying an additional 126,837 shares during the period. Institutional investors own 89.07% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.